1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Minute Insight: Senseonics Eversense E3 CGM Receives CE Mark, Launch Planned For Q3

 
• By Marion Webb

Sensonics received the CE mark for its next-generation E3 CGM with plans to launch in the third quarter. It will be facing stiff competition from CGM makers Dexcom and Abbott in the European market.   

Minute Insight
• Source: Informa/Alamy

After making its debut in the US, Senseonics Holdings, Inc.’s next-generation, six-month Eversense E3 continuous glucose monitoring (CGM) received a CE mark, the company announced on 16 June. Senseonics plans to launch its Eversense E3 GCM in certain European countries starting in the third quarter.

Both, the implantable Eversense E3 CGM and Eversense XL CGM (available in Europe since 2017), have a 180-day sensor, but the new E3 system is specifically designed to lengthen sensor life

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Access To Library Tools Being Restored At US FDA

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.

FDA Announces Classifications On 9 Device Types

 
• By Elizabeth Orr

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.